The Philadelphia Phillies have been hit with one of the most unexpected setbacks of spring training after Major League Baseball officially announced an 80-game suspension tied to a failed performance-enhancing drug test. The timing creates immediate pressure for Philadelphia, which was entering the final phase of camp while still sorting out key outfield decisions before Opening Day.
League officials confirmed that the suspension follows a positive test for Boldenone, an anabolic steroid prohibited under MLB’s drug policy. The player involved attempted to challenge the ruling through appeal, but the decision was upheld, leaving the punishment active immediately and forcing the organization to adjust roster plans much sooner than expected.
The most shocking part is that Johan Rojas will not only miss 80 games, but he will also be automatically ineligible for postseason play even if he returns later in the regular season. That added penalty creates an even larger long-term concern for Philadelphia, especially if the club remains in playoff contention deep into the year.
The suspension also carries a serious financial consequence, as the games missed will come without pay. Based on his current contract structure, Rojas is expected to lose a significant portion of his 2026 earnings while serving the ban, with a possible return projected for late June if the schedule remains uninterrupted.
For the Phillies, the loss arrives just as Rojas was trying to rebuild momentum after an inconsistent 2025 season. He hit .224 last year while providing strong speed and defensive value, but his offensive inconsistency led to reduced opportunities late in the season before he entered camp hoping for a stronger reset.
Now Philadelphia must quickly decide how to fill the defensive gap and protect outfield depth during the opening months of the season. What began as a normal final week of spring training has suddenly become one of the club’s biggest early-season roster challenges